Article Text

other Versions

PDF
Association of Methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry
  1. J D Greenberg (jeffrey.greenberg{at}nyumc.org)
  1. NYU Hospital for Joint Diseases, United States
    1. G Reed (george.reed{at}umassmed.edu)
    1. University of Massachusetts Medical School, United States
      1. J M Kremer (jkremer{at}joint-docs.com)
      1. The Center for Rheumatology, United States
        1. E Tindall (etindall{at}msn.com)
        1. Genentech, Inc., United States
          1. A Kavanaugh (akavanaugh{at}ucsd.edu)
          1. University of California at San Diego, United States
            1. C Zheng (zheng.jason{at}gene.com)
            1. Genentech, Inc., United States
              1. W Bishai (wbishai{at}jhmi.edu)
              1. Johns Hopkins University, United States
                1. M Hochberg (mhochber{at}medicine.umaryland.edu)
                1. University of Maryland on behalf of the CORRONA Investigators, United States

                  Abstract

                  Objective: To examine the association of methotrexate (MTX) and TNF antagonists with risk of infectious outcomes including opportunistic infections in patients with rheumatoid arthritis (RA).

                  Methods: RA patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) registry prescribed MTX, TNF antagonists or other disease modifying anti-rheumatic drugs (DMARDs) were included. The primary outcomes were incident overall and opportunistic infections. Incident rate ratios were calculated using Generalized Estimating Equation (GEE) Poisson regression models adjusted for demographics, comorbidities and RA disease activity measures.

                  Results: A total of 7,971 RA patients were followed. Adjusted rate of infections per 100 person-years was increased among MTX (30.9, 95% CI [29.2, 32.7]), TNF antagonist (40.1, 95% CI [37.0, 43.4]) and combination MTX/TNF antagonist users (37.1, 95% CI [34.9, 39.3]) versus other nonbiologic DMARD users (24.5, 95% CI [21.8, 27.5]). The adjusted incidence rate ratio (IRR) was increased for patients prescribed MTX (IRR 1.30, 95% CI 1.12-1.50) and TNF antagonists (IRR 1.52, 95% CI 1.30-1.78) compared to other DMARD users. For opportunistic infections, TNF antagonist use (IRR 1.67, 95% CI 0.95-2.94) was associated with increased risk. Prednisone use was associated with an increased risk of opportunistic infection (IRR 1.63, 95% CI 1.20-2.21) and an increased risk of overall infection at doses > 10 mg daily (IRR 1.30, 95% CI 1.11-1.53).

                  Conclusions: MTX, TNF antagonists and prednisone at doses >10 mg daily were associated with increased risks of overall infections. Low-dose prednisone and TNF antagonists, but not MTX, increased risk for opportunistic infections.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.